NasdaqCM - Delayed Quote • USD
Instil Bio, Inc. (TIL)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:06 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -2.23 | -2.3 | -6.35 | -9.05 |
| Low Estimate | -2.3 | -2.38 | -10.22 | -14.38 |
| High Estimate | -2.16 | -2.22 | -0.85 | -0.43 |
| Year Ago EPS | -8.8 | -2.8 | -24 | -6.35 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -3.1 | -3.27 | -2 | -2.84 |
| EPS Actual | -8.8 | -2.8 | -10.4 | -1.99 |
| Difference | -5.7 | 0.47 | -8.4 | 0.85 |
| Surprise % | -183.90% | 14.40% | -420.00% | 29.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -2.23 | -2.3 | -6.35 | -9.05 |
| 7 Days Ago | -2.23 | -2.3 | -9.1 | -13.35 |
| 30 Days Ago | -2.99 | -3.01 | -11.79 | -0.71 |
| 60 Days Ago | -2.99 | -3.01 | -11.79 | -0.71 |
| 90 Days Ago | -3 | -3.06 | -11.98 | -0.71 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 2 | 2 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TIL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 74.70% | -- | -- | 1.60% |
| Next Qtr. | 17.90% | -- | -- | 10.50% |
| Current Year | 73.50% | -- | -- | 5.20% |
| Next Year | -42.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | Jefferies: Buy to Hold | 4/12/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/25/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/22/2024 |
| Reiterates | Baird: Outperform to Outperform | 1/19/2024 |
| Maintains | Baird: Outperform to Outperform | 1/17/2024 |
Related Tickers
ASMB Assembly Biosciences, Inc.
13.41
+0.60%
ACHL Achilles Therapeutics plc
0.7829
-2.14%
CTMX CytomX Therapeutics, Inc.
1.6700
-3.47%
SPRO Spero Therapeutics, Inc.
1.4000
-4.76%
NXTC NextCure, Inc.
1.6000
+1.91%
PRTC PureTech Health plc
26.15
-0.46%
GLPG.AS Galapagos NV
27.18
-0.73%
PRTC.L PureTech Health plc
206.50
-0.48%
CLRB Cellectar Biosciences, Inc.
3.0300
-0.33%
RPHM Reneo Pharmaceuticals, Inc.
1.7400
-1.14%